Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 4Completed 4Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Uterine Cervical Neoplasms 4Breast Neoplasms 4Oropharyngeal Neoplasms 3Sarcoma 2Prostatic Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymus Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1

Interventions

pembrolizumab 46Cisplatin 31Carboplatin 20Cetuximab 16Nivolumab 15Paclitaxel 14Radiotherapy, Intensity-Modulated 12Radiotherapy 10Docetaxel 10Fluorouracil 9Platinum 8durvalumab 7Taxes 71,2-diaminocyclohexaneplatinum II citrate 7Radiation 6tislelizumab 5Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5cemiplimab 4avelumab 4Specimen Handling 4Radiosurgery 4Drug Therapy 4Biopsy 4130-nm albumin-bound paclitaxel 4tremelimumab 3palbociclib 3olaparib 3dostarlimab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Squamous Cell Carcinoma of Head and Neck × Fluorodeoxyglucose F18 × Clear all
NCT03952585 2026-06-01

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
384 enrolled 22 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡